Re-Defining the Membrane
Straumann® MembraGel
Advanced technology membrane
which sets new standards in GBR
Undisturbed healing is a prerequisite for the successful esthetic outcome of GBR
­procedures. Consequently, GBR membranes are required to:
Stabilize the underlying bone graft and
Effectively prevent the ingrowth of soft tissue into the surgical site during
the process of bone healing before the GBR membranes are biodegraded.
Furthermore, an easy-to-use membrane should help to simplify the surgical procedure.
Straumann® MembraGel combines unique material features which are designed to
support undisturbed bone healing and to simplify the surgical procedure:
Optimized barrier function
Stabilizes the bone graft
Precise and easy application
“Straumann® MembraGel is a key innovation in ­
Guided Bone
­Regeneration. With the PEG technology we are on the verge of
some­thing new, entering into a new era in oral tissue regeneration.”
Prof. Christoph Hämmerle (University of Zurich)
Optimized barrier function
Straumann® MembraGel with its optimized barrier properties effectively prevents
gingival soft tissue from entering the protected area over a period of 4–6 months,
Cell infiltration (in % of positive control
without membrane)
thereby supporting new bone formation.
10
9
8
7
6
5
4
3
2
1
0
1
2
3,1
4,3
4,6
6
7
Months after implantation
Straumann® MembraGel implanted subcutaneously in rats. Only after 4.3 months
was a significant change in the number of cells that passed the barrier d
­ etectable1
Straumann® MembraGel is designed for prolonged integrity of the membrane in
­order to enhance the protection of the regenerating bone.
8
Collagen membrane
Straumann® MembraGel
120
7
80
60
40
4.3 mm bone gain
= 96 % defect fill
5
4
3
2
20
0
5.6 mm bone gain
= 95 % defect fill
6
100
Defect in mm
Residual membrane thickness (%)
140
1
1
2
4
8
16
Weeks after implantation
Straumann® MembraGel biodegrades significantly slower than a standard
collagen membrane; shown in a study in rats 2
24
0
Initial
defect
Residual
defect
Straumann® MembraGel
(n=19)
Initial
defect
Residual
defect
Collagen Membrane
(n=18)
Effective bone augmentation. Defect resolution of bone dehiscence defects
6 months postoperatively, demonstrated in a randomized, controlled
clinical trial. The differences in % defect fill were not significant 3
Stabilizes the bone graft
Once solidified in situ, Straumann® MembraGel stabilizes the underlying bone graft
aiming at undisturbed bone regeneration.
Proportion of newly formed bone
(% area fraction)
Straumann® MembraGel solidifies in situ 20–50 seconds after application.
The underlying bone graft material is stabilized and confined to the site of bone
augmentation
35
30
20.3
18.9
Straumann®
MembraGel
(n=12)
ePTFE
(n=10)
25
20
15
7.3
10
5
0
No membrane
(n=10)
Bone area fraction from a histological study in rats. Differences between the two
membranes were statistically not significant 4
Precise and easy application
Precise application to the surgical site
Adaptation to various types and sizes of bone defects
Due to its gel-like consistency Straumann® MembraGel can be precisely applied
to the surgical site
Designed for improving GBR procedures
Effective support in bone formation for GBR cases due to optimized barrier
­p roperties
Undisturbed bone healing as a basis for the optimal clinical outcome achieved
by stabilization of the bone graft material
Simplified surgical procedure by precise and easy application
Continuing education and technological advances
Straumann ® MembraGel Exclusive Education Program
Personal experience in a hands-on workshop
In-depth information on pre-clinical and clinical evidence
Learn about surgical techniques and clinical aspects of this novel technology
Join in one of the Straumann ® MembraGel Education Events in your region. Ask a
Straumann representative for further details about Straumann® MembraGel Education
Events.
Hands-on workshop during a Straumann® MembraGel Education Event
“Every product should be launched in combination with an educational program. When a new product is introduced it should be
something new, different from the previous ­products and hopefully it
should be better. So, people need to be told about the improvements
and be educated.”
Prof. Christoph Hämmerle (University of Zurich)
1
Wechsler S, Fehr D, Molenberg A, Raeber G, Schense J, Weber F. A novel, tissue occlusive poly(ethylene glycol) hydrogel material. J. Biomed. Mater. Res. A 2008
Herten M, Jung R, Ferrari D, Rothamel D, Golubovic V, Molenberg A, Hämmerle Ch, Becker J, Schwarz F. Biodegradation of different synthetic hydrogels made of
2
polyethylene glycol hydrogel/RGD-peptide modifications: an immunohistochemical study in rats. Clin Oral Implants Res. 2009 Feb;20(2):116-25
Jung RE, Hälg GA, Thoma DS, Hämmerle CH. A randomized, controlled clinical trial to evaluate a new membrane for guided bone regeneration around dental
3
­implants. Clin Oral Implants Res. 2009 Feb;20(2):162-8
Jung RE, Zwahlen R, Weber FE, Molenberg A, van Lenthe GH, Hämmerle CH. Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for
4
guided bone regeneration. Clin Oral Implants Res. 2006 Aug;17(4):426-33
w w w. s t rau m an n .c o m
© Institut Straumann AG, 2011. All rights reserved.
Straumann® and/or other trademarks and logos from Straumann® mentioned herein are the trademarks or registered trademarks of Straumann Holding AG
and/or its affiliates. All rights reserved.
02/11
International Headquarters
Institut Straumann AG
Peter Merian-Weg 12
CH-4002 Basel, Switzerland
Phone +41 (0)61 965 11 11
Fax +41 (0)61 965 11 01